'IMB-101(OXTIMA),' a dual-antibody candidate jointly developed by HK inno. N, IMBiologics, and Y-Biologics, was licensed out to a U.S. biotech company specializing in new drug development.

The contract amounts to US$940 million (approximately KRW 1.3 trillion), including an up-front payment of US$20 million (KRW 27.6 billion).

HK inno. N announced on June 17th that it has entered into a technology transfer agreement with Navigator Medicines, a U.S. new drug development company.

The contract covers global countries except for Asia (Japan included). According to the contract, HK inno. N will receive a proportional share of the total contract. The company will also r